GC녹십자-목암생명과학연구소, 서울대 AI 연구원과 신약 개발 공동연구 협력허은철 GC녹십자 대표 및 정재욱 목암연구소장, 장병탁 서울대 AI 연구원장, 함종민 CIC센터장 등이 참석한 가운데 진행
*아래는 위 기사를 구글 번역기로 번역한 영문 기사의 [전문]이다. [Below is the [full text] of an English article translated from the above article with Google Translate.
GC Green Cross-Mokam Life Science Research Center and Seoul National University AI Researcher Collaborate on New Drug Development Joint Research
Heo Eun-cheol, CEO of GC Green Cross, Jeong Jae-wook, head of Mok Cancer Research Center, Jang Byung-tak, president of AI Research at Seoul National University, and Ham Jong-min, head of CIC Center were in attendance.
[Introduction to the case/ Reporter Park Yeon-pa] = GC Green Cross (CEO Eun-cheol Huh) and the Mokam Life Science Research Institute (Director Jae-wook Jung, hereafter referred to as the Mokam Research Institute) collaborated with the AI Researcher of Seoul National University to build an AI drug research platform in Mokam Town, Yongin, Gyeonggi-do. It was announced on the 25th that it had signed a research agreement.
The signing ceremony was held in the presence of GC CEO Eun-cheol Huh, head of Mokam Research Center Jae-wook Jeong, director of AI Research Center at Seoul National University Byung-tak Jang, and director of CIC Center Ham Jong-min in attendance.
Through the agreement, the two sides will cooperate to “discover new drug candidates and establish a disease-related genome and protein research platform” using various AI algorithms. The two companies plan to promote joint research across diseases and new drug development, including △substance screening, △prediction of efficacy, and △detection of mutations.
According to this agreement, GC Green Cross and Mokam Research Institute will participate in the Seoul National University AI Researcher's membership program. The company explained that it will create synergy by grafting the AI platform to the development of a treatment for rare diseases using ‘messenger ribonucleic acid (mRNA)’, which is being carried out centering on the Mok Cancer Research Center.
This case is significant in that it is the first collaboration between Korea's largest AI research organization and a pharmaceutical company. Since the development of new drugs takes a lot of time and cost, there is a trend of active movement using AI around the world.
Byung-Tak Jang, Director of AI Research at Seoul National University, said, “Through GC Green Cross, Seoul National University’s new drug development research will have the opportunity to be realized in a variety of ways in the real world. I hope it will happen,” he said.
Jung Jae-wook, director of the Mok Cancer Research Institute, said, “With this cooperation, the AI platform, which the Mok Cancer Research Institute has been preparing since 2021, will be practically applied to new drug development such as disease-related genome research, mRNA platform research, and rare disease research. ” he said.
<저작권자 ⓒ 사건의내막 무단전재 및 재배포 금지>
관련기사목록
|
인기기사
|